Barclays’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-39
Closed 6709
2019
Q4
$0 Sell
39
-1,088
-97% -$3.46K ﹤0.01% 7115
2019
Q3
$3K Buy
+1,127
New +$3.17K ﹤0.01% 6529
2019
Q2
Sell
-1,124
Closed -$4K 7505
2019
Q1
$4K Buy
1,124
+407
+57% +$1.52K ﹤0.01% 6780
2018
Q4
$3K Sell
717
-6,749
-90% -$29.4K ﹤0.01% 6669
2018
Q3
$43K Sell
7,466
-13,180
-64% -$75.4K ﹤0.01% 6168
2018
Q2
$104K Sell
20,646
-96,750
-82% -$498K ﹤0.01% 5219
2018
Q1
$602K Buy
117,396
+110,801
+1,680% +$667K ﹤0.01% 3773
2017
Q4
$40K Buy
+6,595
New +$39.7K ﹤0.01% 5887
2017
Q3
Sell
-149
Closed -$1K 7172
2017
Q2
$1K Hold
149
﹤0.01% 6568
2017
Q1
$1K Sell
149
-1,107
-88% -$10.7K ﹤0.01% 6691
2016
Q4
$14K Sell
1,256
-261,280
-100% -$2.46M ﹤0.01% 5793
2016
Q3
$2.43M Buy
262,536
+259,741
+9,293% +$2.17M ﹤0.01% 1837
2016
Q2
$17K Sell
2,795
-663
-19% -$4.4K ﹤0.01% 5345
2016
Q1
$21K Buy
3,458
+2,921
+544% +$18.8K ﹤0.01% 5205
2015
Q4
$4K Buy
537
+419
+355% +$3.13K ﹤0.01% 5642
2015
Q3
$1K Sell
118
-6,015
-98% -$61.3K ﹤0.01% 6683
2015
Q2
$61K Buy
+6,133
New +$67.8K ﹤0.01% 5025
2014
Q4
Sell
-5,700
Closed -$29K 7746
2014
Q3
$29K Buy
+5,700
New +$32.7K ﹤0.01% 6254

Barclays's FOMX Position: Q1 2020 in Review

Barclays sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2020, closing a stake of 39 shares.

Barclays first reported a position in FOMX in Q3 2014 and held it in 18 quarters. The position peaked at $2.43M in Q3 2016. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.

  • Barclays reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2020 after selling out during the quarter.
  • Barclays sold 39 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2020.
  • Barclays first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q3 2014 and held it in 18 quarters.
  • Barclays's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $2.43M in Q3 2016.
  • 3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2020.

Based on Barclays's 13F filing for Q1 2020, filed 13 May 2020.